Semaglutide GLP-1 (Wegovy): Semaglutide GLP-1 is available as a weekly injectable option that many patients find convenient
Common adverse effects include gastrointestinal symptoms, which affect the majority of patients to varying degrees: Nausea (20-44% of patients) usually most pronounced during dose escalation Diarrhea (20-30%) Constipation (15-24%) Vomiting (9-24%) Abdominal pain (6-10%) These symptoms typically diminish over time as physiological adaptation occurs
In This Article What the TrumpRX Deal Actually Says If your insurance covers GLP-1 medications, youre likely already receiving a substantial discount
For those experiencing significant appetite suppression, scheduling meal and snack times might be necessary to ensure nutritional needs are met
Instead, it is best to use these medications exactly as prescribed by your provider
The FDAs updated label now highlights the risk of ileus, a condition where the intestines cannot move food properly, which can lead to severe blockages